// App-Quantinova.ai

TPS654 : Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.

Researchers

Presenter

  • Erica L. Mayer

Principal Investigators

  • Adrienne Brana Gropper

  • William Thomas Barry

  • Eric P. Winer

  • Harold J. Burstein

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Massachusetts General Hospital Cancer Center, Boston, MAMemorial Sloan Kettering Cancer Center, New York, NYDana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Anastrozole

  • Palbociclib

  • Exemestane

  • NSC-163501

Outcome

  • Unknown

Study Design

  • single arm

Phase

  • II

Study Id's

  • NCT02040857

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved